Inhibition of the MEK-ERK signaling pathway reverses acquired osimertinib resistance in NSCLC attributed to AXL overexpression.

Authors

Kai Zhang, Xiying Yu, Yue Liu, Huan Zhang, Xin Wang, Peng Jiang, Xiaomi Li, Yang Su, Yuan Gao, Hongqian Chu, Tongmei Zhang, Hongxia Li

Published in

Life sciences. Pages 124739. Oct 13, 2026. Epub Oct 13, 2026.

Abstract

Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is the standard first-line treatment for patients with EGFR-activating mutation of late-stage non-small cell lung cancer (NSCLC), but the emergence of acquired resistance limits its efficacy in real use. The overexpression of anexelekto (AXL) is known to be associated with acquired resistance to osimertinib. However, the specific mechanisms of AXL-mediated resistance are not well explained, nor of the specific therapeutic approaches in patients for this. In this study, we identified that activation of MEK-ERK pathway played a key role in AXL-driven acquired osimertinib resistance in NSCLC. Inhibition of the MEK-ERK activation restored osimertinib sensitivity in AXL-driven resistant tumor cells. The combination use of MEK inhibitor with osimertinib reversed the aquierd osimertinib resistance in vitor and in vivo. Our findings provide preclinical mechanistic support for potential use to targeting MEK-ERK signaling in AXL-associated osimertinib resistance and forfurther validation in patient-derived and clinical models.

PMID:
42869130
Bibliographic data and abstract were imported from PubMed on 14 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.